HSBC TUR.WAR.OP.END. VIA/ DE000HS36M88 /
11/10/2024 21:36:17 | Chg.+0.0400 | Bid21:58:51 | Ask21:58:51 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
1.7200EUR | +2.38% | 1.7200 Bid Size: 10,000 |
1.8100 Ask Size: 10,000 |
Viatris Inc | 9.5682 USD | 31/12/2078 | Call |
GlobeNewswire
07/08
Intra-Cellular Therapies Announces Appointment of Sanjeev Narula as Chief Financial Officer
GlobeNewswire
03/06
Aquestive Therapeutics Announces Executive Appointments and Builds Commercial Capabilities
GlobeNewswire
10/05
Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update
GlobeNewswire
06/05
Ocuphire Pharma Announces Presentation on APX3330 at the ARVO 2024 Annual Meeting
GlobeNewswire
11/04
First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS...
GlobeNewswire
01/04
Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) b...
GlobeNewswire
20/03
Lifecore Biomedical Concludes Strategic Evaluation Process, Announces Management Succession and Boar...
GlobeNewswire
08/03
Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corpo...
GlobeNewswire
28/02
Idorsia and Viatris enter into a significant global research and development collaboration
GlobeNewswire
14/02
ACTG Announces Launch of Clinical Trial Evaluating Drug-Drug Interaction in Shortened Tuberculosis R...
GlobeNewswire
05/02
Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degener...
GlobeNewswire
02/02
Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
GlobeNewswire
04/01
Ocuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of...
GlobeNewswire
02/01
VIATRIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Viatris Inc. on Behalf of Long-Term Stoc...
GlobeNewswire
30/11/2023
Ocuphire Pharma Announces Presentation at Ophthalmology Innovation Summit (OIS) XIII
GlobeNewswire
30/11/2023
Biocon Biologics Successfully Completes Integration of Viatris’ Biosimilar Business in 31 Countries ...
GlobeNewswire
27/11/2023
Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)